Selected research
Industry Research
Plasma Derived Medicine Industry Research Report 2026
Market perspective
The global Plasma Derived Medicine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Plasma Derived Medicine market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Plasma Derived Medicine market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Plasma Derived Medicine market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Plasma Derived Medicine include Yuanda Shuyang, Takeda, Weiguang Bio, Tiantan Bio, CBPO, Shuanglin Bio, RAAS, Nanyue Bio and Hualan Bio, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Plasma Derived Medicine market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Plasma Derived Medicine.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Plasma Derived Medicine Market by Company
Yuanda Shuyang
Takeda
Weiguang Bio
Tiantan Bio
CBPO
Shuanglin Bio
RAAS
Nanyue Bio
Hualan Bio
Boya Bio
Octapharma
LFB Group
KM Biologics
Kedrion
Grifols
CSL
BPL
Biotest
Plasma Derived Medicine Segment by Type
Albumin
Immune Globulin
Coagulation Factor
Others
Plasma Derived Medicine Segment by Application
Hospital
Retail Pharmacy
Other
Plasma Derived Medicine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Plasma Derived Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Plasma Derived Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Plasma Derived Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Plasma Derived Medicine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Albumin
- Immune Globulin
- Coagulation Factor
- Others
Applications
- Hospital
- Retail Pharmacy
- Other
Companies covered
- Yuanda Shuyang
- Takeda
- Weiguang Bio
- Tiantan Bio
- CBPO
- Shuanglin Bio
- RAAS
- Nanyue Bio
- Hualan Bio
- Boya Bio
- Octapharma
- LFB Group
- KM Biologics
- Kedrion
- Grifols
- CSL
- BPL
- Biotest
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Plasma Derived Medicine by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Albumin
- 2.2.3 Immune Globulin
- 2.2.4 Coagulation Factor
- 2.2.5 Others
- 2.3 Plasma Derived Medicine by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Retail Pharmacy
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Plasma Derived Medicine Breakdown Data by Type
- 3.1 Global Plasma Derived Medicine Historic Market Size by Type (2021-2026)
- 3.2 Global Plasma Derived Medicine Forecasted Market Size by Type (2027-2032)
4 Plasma Derived Medicine Breakdown Data by Application
- 4.1 Global Plasma Derived Medicine Historic Market Size by Application (2021-2026)
- 4.2 Global Plasma Derived Medicine Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Plasma Derived Medicine Market Perspective (2021-2032)
- 5.2 Global Plasma Derived Medicine Growth Trends by Region
- 5.2.1 Global Plasma Derived Medicine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Plasma Derived Medicine Historic Market Size by Region (2021-2026)
- 5.2.3 Plasma Derived Medicine Forecasted Market Size by Region (2027-2032)
- 5.3 Plasma Derived Medicine Market Dynamics
- 5.3.1 Plasma Derived Medicine Industry Trends
- 5.3.2 Plasma Derived Medicine Market Drivers
- 5.3.3 Plasma Derived Medicine Market Challenges
- 5.3.4 Plasma Derived Medicine Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Plasma Derived Medicine Players by Revenue
- 6.1.1 Global Top Plasma Derived Medicine Players by Revenue (2021-2026)
- 6.1.2 Global Plasma Derived Medicine Revenue Market Share by Players (2021-2026)
- 6.2 Global Plasma Derived Medicine Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Plasma Derived Medicine Head Office and Area Served
- 6.4 Global Plasma Derived Medicine Players, Product Type & Application
- 6.5 Global Plasma Derived Medicine Manufacturers Established Date
- 6.6 Global Plasma Derived Medicine Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Plasma Derived Medicine Market Size (2021-2032)
- 7.2 North America Plasma Derived Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Plasma Derived Medicine Market Size by Country (2021-2026)
- 7.4 North America Plasma Derived Medicine Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Plasma Derived Medicine Market Size (2021-2032)
- 8.2 Europe Plasma Derived Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Plasma Derived Medicine Market Size by Country (2021-2026)
- 8.4 Europe Plasma Derived Medicine Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Plasma Derived Medicine Market Size (2021-2032)
- 9.2 Asia-Pacific Plasma Derived Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Plasma Derived Medicine Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Plasma Derived Medicine Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Plasma Derived Medicine Market Size (2021-2032)
- 10.2 South America Plasma Derived Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Plasma Derived Medicine Market Size by Country (2021-2026)
- 10.4 South America Plasma Derived Medicine Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Plasma Derived Medicine Market Size (2021-2032)
- 11.2 Middle East & Africa Plasma Derived Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Plasma Derived Medicine Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Plasma Derived Medicine Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Yuanda Shuyang
- 12.1.1 Yuanda Shuyang Company Information
- 12.1.2 Yuanda Shuyang Business Overview
- 12.1.3 Yuanda Shuyang Revenue in Plasma Derived Medicine Business (2021-2026)
- 12.1.4 Yuanda Shuyang Plasma Derived Medicine Product Portfolio
- 12.1.5 Yuanda Shuyang Recent Developments
- 12.2 Takeda
- 12.2.1 Takeda Company Information
- 12.2.2 Takeda Business Overview
- 12.2.3 Takeda Revenue in Plasma Derived Medicine Business (2021-2026)
- 12.2.4 Takeda Plasma Derived Medicine Product Portfolio
- 12.2.5 Takeda Recent Developments
- 12.3 Weiguang Bio
- 12.3.1 Weiguang Bio Company Information
- 12.3.2 Weiguang Bio Business Overview
- 12.3.3 Weiguang Bio Revenue in Plasma Derived Medicine Business (2021-2026)
- 12.3.4 Weiguang Bio Plasma Derived Medicine Product Portfolio
- 12.3.5 Weiguang Bio Recent Developments
- 12.4 Tiantan Bio
- 12.4.1 Tiantan Bio Company Information
- 12.4.2 Tiantan Bio Business Overview
- 12.4.3 Tiantan Bio Revenue in Plasma Derived Medicine Business (2021-2026)
- 12.4.4 Tiantan Bio Plasma Derived Medicine Product Portfolio
- 12.4.5 Tiantan Bio Recent Developments
- 12.5 CBPO
- 12.5.1 CBPO Company Information
- 12.5.2 CBPO Business Overview
- 12.5.3 CBPO Revenue in Plasma Derived Medicine Business (2021-2026)
- 12.5.4 CBPO Plasma Derived Medicine Product Portfolio
- 12.5.5 CBPO Recent Developments
- 12.6 Shuanglin Bio
- 12.6.1 Shuanglin Bio Company Information
- 12.6.2 Shuanglin Bio Business Overview
- 12.6.3 Shuanglin Bio Revenue in Plasma Derived Medicine Business (2021-2026)
- 12.6.4 Shuanglin Bio Plasma Derived Medicine Product Portfolio
- 12.6.5 Shuanglin Bio Recent Developments
- 12.7 RAAS
- 12.7.1 RAAS Company Information
- 12.7.2 RAAS Business Overview
- 12.7.3 RAAS Revenue in Plasma Derived Medicine Business (2021-2026)
- 12.7.4 RAAS Plasma Derived Medicine Product Portfolio
- 12.7.5 RAAS Recent Developments
- 12.8 Nanyue Bio
- 12.8.1 Nanyue Bio Company Information
- 12.8.2 Nanyue Bio Business Overview
- 12.8.3 Nanyue Bio Revenue in Plasma Derived Medicine Business (2021-2026)
- 12.8.4 Nanyue Bio Plasma Derived Medicine Product Portfolio
- 12.8.5 Nanyue Bio Recent Developments
- 12.9 Hualan Bio
- 12.9.1 Hualan Bio Company Information
- 12.9.2 Hualan Bio Business Overview
- 12.9.3 Hualan Bio Revenue in Plasma Derived Medicine Business (2021-2026)
- 12.9.4 Hualan Bio Plasma Derived Medicine Product Portfolio
- 12.9.5 Hualan Bio Recent Developments
- 12.10 Boya Bio
- 12.10.1 Boya Bio Company Information
- 12.10.2 Boya Bio Business Overview
- 12.10.3 Boya Bio Revenue in Plasma Derived Medicine Business (2021-2026)
- 12.10.4 Boya Bio Plasma Derived Medicine Product Portfolio
- 12.10.5 Boya Bio Recent Developments
- 12.11 Octapharma
- 12.11.1 Octapharma Company Information
- 12.11.2 Octapharma Business Overview
- 12.11.3 Octapharma Revenue in Plasma Derived Medicine Business (2021-2026)
- 12.11.4 Octapharma Plasma Derived Medicine Product Portfolio
- 12.11.5 Octapharma Recent Developments
- 12.12 LFB Group
- 12.12.1 LFB Group Company Information
- 12.12.2 LFB Group Business Overview
- 12.12.3 LFB Group Revenue in Plasma Derived Medicine Business (2021-2026)
- 12.12.4 LFB Group Plasma Derived Medicine Product Portfolio
- 12.12.5 LFB Group Recent Developments
- 12.13 KM Biologics
- 12.13.1 KM Biologics Company Information
- 12.13.2 KM Biologics Business Overview
- 12.13.3 KM Biologics Revenue in Plasma Derived Medicine Business (2021-2026)
- 12.13.4 KM Biologics Plasma Derived Medicine Product Portfolio
- 12.13.5 KM Biologics Recent Developments
- 12.14 Kedrion
- 12.14.1 Kedrion Company Information
- 12.14.2 Kedrion Business Overview
- 12.14.3 Kedrion Revenue in Plasma Derived Medicine Business (2021-2026)
- 12.14.4 Kedrion Plasma Derived Medicine Product Portfolio
- 12.14.5 Kedrion Recent Developments
- 12.15 Grifols
- 12.15.1 Grifols Company Information
- 12.15.2 Grifols Business Overview
- 12.15.3 Grifols Revenue in Plasma Derived Medicine Business (2021-2026)
- 12.15.4 Grifols Plasma Derived Medicine Product Portfolio
- 12.15.5 Grifols Recent Developments
- 12.16 CSL
- 12.16.1 CSL Company Information
- 12.16.2 CSL Business Overview
- 12.16.3 CSL Revenue in Plasma Derived Medicine Business (2021-2026)
- 12.16.4 CSL Plasma Derived Medicine Product Portfolio
- 12.16.5 CSL Recent Developments
- 12.17 BPL
- 12.17.1 BPL Company Information
- 12.17.2 BPL Business Overview
- 12.17.3 BPL Revenue in Plasma Derived Medicine Business (2021-2026)
- 12.17.4 BPL Plasma Derived Medicine Product Portfolio
- 12.17.5 BPL Recent Developments
- 12.18 Biotest
- 12.18.1 Biotest Company Information
- 12.18.2 Biotest Business Overview
- 12.18.3 Biotest Revenue in Plasma Derived Medicine Business (2021-2026)
- 12.18.4 Biotest Plasma Derived Medicine Product Portfolio
- 12.18.5 Biotest Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst